Literature DB >> 11714701

The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63.

Viola Calabrò1, Gelsomina Mansueto, Tiziana Parisi, Maria Vivo, Raffaele A Calogero, Girolama La Mantia.   

Abstract

Genetic alteration of the p53 tumor suppressor gene, which monitors DNA damage and operates cell cycle checkpoints, is a major factor in the development of human malignancies. The p53 protein belongs to a family that also includes two structurally related proteins, p63 and p73. Although all three proteins share similar transcriptional functions and antiproliferative effects, each of them appears to play a distinct role in development and tumor suppression. One of the principal regulators of p53 activity is the MDM2 protein. The interaction of MDM2 with p53 inhibits p53 transcriptional activity and targets p53 for ubiquitin-dependent degradation. The ability of MDM2 to inhibit p53 functions is antagonized by the ARF oncosuppressor protein. We show here that like p53, the p63alpha and p63gamma isoforms are able to associate with human MDM2 (HDM2). Overexpression of HDM2 increased the steady-state level of intracellular p63 and enhanced its transcriptional activity. Both effects appeared to be counteracted by ARF coexpression. These data indicate that p63 can be activated by HDM2 under conditions in which p53 is inhibited. Therefore, HDM2 expression could support p63-specific transcriptional functions on a common set of genes, keeping interference by p53 at a minimum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714701     DOI: 10.1074/jbc.M107173200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains.

Authors:  Pamela Ghioni; Fabrizio Bolognese; Pascal H G Duijf; Hans Van Bokhoven; Roberto Mantovani; Luisa Guerrini
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

Review 2.  Dlx genes, p63, and ectodermal dysplasias.

Authors:  Maria I Morasso; Nadezda Radoja
Journal:  Birth Defects Res C Embryo Today       Date:  2005-09

Review 3.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

4.  The Mdm2 ubiquitin ligase enhances transcriptional activity of human papillomavirus E2.

Authors:  Noor Gammoh; Daniela Gardiol; Paola Massimi; Lawrence Banks
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

5.  Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase.

Authors:  L E Giono; L Resnick-Silverman; L A Carvajal; S St Clair; J J Manfredi
Journal:  Oncogene       Date:  2017-08-14       Impact factor: 9.867

6.  Differences in the transactivation domains of p53 family members: a computational study.

Authors:  Jagadeesh N Mavinahalli; Arumugam Madhumalar; Roger W Beuerman; David P Lane; Chandra Verma
Journal:  BMC Genomics       Date:  2010-02-10       Impact factor: 3.969

7.  Splicing up mdm2 for cancer proteome diversity.

Authors:  Danielle R Okoro; Melissa Rosso; Jill Bargonetti
Journal:  Genes Cancer       Date:  2012-03

8.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03

9.  ASPP1 and ASPP2: common activators of p53 family members.

Authors:  Daniele Bergamaschi; Yardena Samuels; Boquan Jin; Sai Duraisingham; Tim Crook; Xin Lu
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

10.  A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism.

Authors:  Zach Serber; Helen C Lai; Annie Yang; Horng D Ou; Martina S Sigal; Alexander E Kelly; Beatrice D Darimont; Pascal H G Duijf; Hans Van Bokhoven; Frank McKeon; Volker Dötsch
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.